Adam Diehl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Adam Diehl has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Alex Rajewski
Cedars-Sinai Med Cntr, Los Angeles, CA
19 shared publications - Annie Blair Richardson
Cure First, Bothell, Washington
19 shared publications - Brady Bernard
Cure First, Bothell, Washington
19 shared publications - Carla Grandori
Cure First, Bothell, Washington
19 shared publications - Christopher J. Kemp
Fred Hutchinson Cancer Center 7 Human Biology Division Seattle, Washington
19 shared publications - Gentry G. King
Fred Hutchinson Cancer Center, University of Washington, Seattle, WA
19 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Supplementary Table S4. Drugs tested for each tumor organoid culture.
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Supplementary Table S4. Drugs tested for each tumor organoid culture.
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Brightfield images of BTC organoid cultures
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Brightfield images of BTC organoid cultures
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Clinical characteristics of the BTC cohort
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Clinical characteristics of the BTC cohort
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Supplementary Table 3. Cholangiocarcinoma genomic landscape from The Cancer Genome Atlas (TCGA) and comparison to this BTC cohort.
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Supplementary Table 3. Cholangiocarcinoma genomic landscape from The Cancer Genome Atlas (TCGA) and comparison to this BTC cohort.
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Tumor organoid confirmation by comparison to third party genomics of the primary tumor
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Tumor organoid confirmation by comparison to third party genomics of the primary tumor
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Biliary tract cancers (BTC) pose clinical challenges due to poor chemotherapy response and aggressive disease course. We evaluated patient-derived tumor organoid–based drug sensitivity testing as a tool to guide therapy. In this multicenter study, 26 tumor organoids were successfully derived from 43 patients with BTC and tested with an average of 50 cancer-directed therapies using the Clinical Laboratory Improvement Amendments–certified PARIS assay. Despite most organoids being from late-stage disease, 24/26 (92.3%) exhibited strong sensitivity to one or more targeted agents. Active drugs included inhibitors of EGFR/HER2, MEK, ERK, BCR-ABL and SRC family, mTOR, PI3K, MDM2, BCL2, and BET. Drug sensitivities aligned with known genetic biomarkers but were also observed in cultures lacking them, indicating ex vivo testing can expand actionability beyond genomics. In five cases, results guided therapy; one patient with an FGFR-BICC1 fusion refractory to FGFR inhibitors responded to dasatinib, achieving symptomatic improvement, stable disease, and >8-month survival. Significance:Ex vivo drug testing of tumor-derived organoids is clinically feasible and can be used to identify personalized treatment options for patients with BTC, to evaluate the functional relevance of genomic biomarkers, and to guide treatment in real time.
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Biliary tract cancers (BTC) pose clinical challenges due to poor chemotherapy response and aggressive disease course. We evaluated patient-derived tumor organoid–based drug sensitivity testing as a tool to guide therapy. In this multicenter study, 26 tumor organoids were successfully derived from 43 patients with BTC and tested with an average of 50 cancer-directed therapies using the Clinical Laboratory Improvement Amendments–certified PARIS assay. Despite most organoids being from late-stage disease, 24/26 (92.3%) exhibited strong sensitivity to one or more targeted agents. Active drugs included inhibitors of EGFR/HER2, MEK, ERK, BCR-ABL and SRC family, mTOR, PI3K, MDM2, BCL2, and BET. Drug sensitivities aligned with known genetic biomarkers but were also observed in cultures lacking them, indicating ex vivo testing can expand actionability beyond genomics. In five cases, results guided therapy; one patient with an FGFR-BICC1 fusion refractory to FGFR inhibitors responded to dasatinib, achieving symptomatic improvement, stable disease, and >8-month survival. Significance:Ex vivo drug testing of tumor-derived organoids is clinically feasible and can be used to identify personalized treatment options for patients with BTC, to evaluate the functional relevance of genomic biomarkers, and to guide treatment in real time.
- Open Access
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Pharmacotype of BTC organoids. A, Heatmap showing PARIS assay results for all targeted drugs tested in at least five organoid cultures. B, Heatmap showing PARIS assay results for all chemotherapeutic agents tested in at least one organoid culture. White rectangles indicate drugs that were not tested in that screen. Asterisks next to a patient number indicate that the drug screen failed some parameter of quality control but was still evaluable.
- 24 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Pharmacotype of BTC organoids. A, Heatmap showing PARIS assay results for all targeted drugs tested in at least five organoid cultures. B, Heatmap showing PARIS assay results for all chemotherapeutic agents tested in at least one organoid culture. White rectangles indicate drugs that were not tested in that screen. Asterisks next to a patient number indicate that the drug screen failed some parameter of quality control but was still evaluable.
- Open Access
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Description of PARIS assay workflow and characterization of the BTC cohort. A, Fresh tumor specimens from patients with BTC were sent to SEngine Precision Medicine for the derivation of organoid cultures (left). The reference organoid photo shown was derived from an ascites sample from a 52-year-old female patient with iCCA (BTC-1). Immunofluorescent staining was performed for DAPI (blue) and pan-keratin (green). The organoid cultures then underwent WES and drug screening, and a ranked drug list was derived from the results (middle). This ranking includes information on targeted, endocrine, and chemotherapeutic agents and can be used by clinicians to guide treatment decisions (right). B, Clinical diagnoses of the cohort of patients with BTC. CCA-NOS, CCA, not otherwise specified; GBC, gallbladder carcinoma. C, Clinical stage of the patients with BTC. D, Clinical procedures used to collect the tumor organoids. E, Anatomic origin of the specimens. F, Treatment exposure history of patients with BTC prior to specimen collection. Any chemotherapeutic treatment, including adjuvant treatment, was counted as a previous treatment. G, Success rates of organoid establishment according to the clinical procedure used to obtain the specimen. H, Success rates of organoid establishment according to the anatomic site of origin. I, Overall success rates of organoid culture derivation and subsequent drug screening. The success rate was calculated for all specimens, including those that were found to have insufficient tumor content. The drug screening success rate was calculated from the number of established organoid cultures. [A, Created in BioRender. Kemp, C. (2026) https://BioRender.com/kv0dbe7.]
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Description of PARIS assay workflow and characterization of the BTC cohort. A, Fresh tumor specimens from patients with BTC were sent to SEngine Precision Medicine for the derivation of organoid cultures (left). The reference organoid photo shown was derived from an ascites sample from a 52-year-old female patient with iCCA (BTC-1). Immunofluorescent staining was performed for DAPI (blue) and pan-keratin (green). The organoid cultures then underwent WES and drug screening, and a ranked drug list was derived from the results (middle). This ranking includes information on targeted, endocrine, and chemotherapeutic agents and can be used by clinicians to guide treatment decisions (right). B, Clinical diagnoses of the cohort of patients with BTC. CCA-NOS, CCA, not otherwise specified; GBC, gallbladder carcinoma. C, Clinical stage of the patients with BTC. D, Clinical procedures used to collect the tumor organoids. E, Anatomic origin of the specimens. F, Treatment exposure history of patients with BTC prior to specimen collection. Any chemotherapeutic treatment, including adjuvant treatment, was counted as a previous treatment. G, Success rates of organoid establishment according to the clinical procedure used to obtain the specimen. H, Success rates of organoid establishment according to the anatomic site of origin. I, Overall success rates of organoid culture derivation and subsequent drug screening. The success rate was calculated for all specimens, including those that were found to have insufficient tumor content. The drug screening success rate was calculated from the number of established organoid cultures. [A, Created in BioRender. Kemp, C. (2026) https://BioRender.com/kv0dbe7.]
- Open Access
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Concordance of ex vivo drug response and genetic biomarkers. A, Heatmap of responses to the FDA-approved FGFR inhibitors futibatinib, infigratinib, and pemigatinib, as well as other FGFR inhibitors derazantinib, AZD4547, dovitinib, lucitanib, and erdafitinib. Dasatinib was included because, as shown here, sensitivity has been detected in several tumors with FGFR alterations that are clinically resistant to FGFR inhibitors. Alterations in FGFR1, FGFR2, and FGFR3 are annotated. B, Heatmap of responses to the HRAS inhibitor tipifarnib; the BRAF inhibitors vemurafenib and dabrafenib; the MEK inhibitors cobimetinib, trametinib, and binimetinib; and the ERK inhibitor ulixertinib. Alterations in KRAS, NRAS, BRAF, and MEK1 are annotated. C, Heatmap of responses to the PI3K inhibitors alpelisib, AZD6482, buparlisib, idelalisib, NVP-BGT226, taselisib, the PI3K/mTOR inhibitor dactolisib, and the mTOR inhibitor everolimus. Alterations in PIK3CA and PIK3CB are annotated. D, Heatmap of responses to the EGFR inhibitors afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, poziotinib, and vandetanib and the ERBB2 inhibitors lapatinib and neratinib. Alterations in EGFR, ERBB2, ERBB3, and ERBB4 are annotated. Asterisks next to a patient number signify that the screen failed a measure of quality control but was still evaluable.
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
Concordance of ex vivo drug response and genetic biomarkers. A, Heatmap of responses to the FDA-approved FGFR inhibitors futibatinib, infigratinib, and pemigatinib, as well as other FGFR inhibitors derazantinib, AZD4547, dovitinib, lucitanib, and erdafitinib. Dasatinib was included because, as shown here, sensitivity has been detected in several tumors with FGFR alterations that are clinically resistant to FGFR inhibitors. Alterations in FGFR1, FGFR2, and FGFR3 are annotated. B, Heatmap of responses to the HRAS inhibitor tipifarnib; the BRAF inhibitors vemurafenib and dabrafenib; the MEK inhibitors cobimetinib, trametinib, and binimetinib; and the ERK inhibitor ulixertinib. Alterations in KRAS, NRAS, BRAF, and MEK1 are annotated. C, Heatmap of responses to the PI3K inhibitors alpelisib, AZD6482, buparlisib, idelalisib, NVP-BGT226, taselisib, the PI3K/mTOR inhibitor dactolisib, and the mTOR inhibitor everolimus. Alterations in PIK3CA and PIK3CB are annotated. D, Heatmap of responses to the EGFR inhibitors afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, poziotinib, and vandetanib and the ERBB2 inhibitors lapatinib and neratinib. Alterations in EGFR, ERBB2, ERBB3, and ERBB4 are annotated. Asterisks next to a patient number signify that the screen failed a measure of quality control but was still evaluable.
- Open Access
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
OncoPrint for the BTC cohort. All structural rearrangements, pathogenic mutations, copy gains, and copy losses of genes taken from clinical histories and third-party NGS sequencing for the BTC cohort are noted. VUSs are not included.
- 31 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer
OncoPrint for the BTC cohort. All structural rearrangements, pathogenic mutations, copy gains, and copy losses of genes taken from clinical histories and third-party NGS sequencing for the BTC cohort are noted. VUSs are not included.